Thomas Lang; MD, PhD (@thomaslangdr) 's Twitter Profile
Thomas Lang; MD, PhD

@thomaslangdr

Global Head Medical Affairs, Access and Partnerships at Novartis Pharma AG; Basel, Switzerland. These are my views.

ID: 3308102337

calendar_today04-06-2015 12:43:27

183 Tweet

311 Takipçi

589 Takip Edilen

Novartis (@novartis) 's Twitter Profile Photo

Scientists worldwide are uniting on 3 key strategies against the #coronavirus, to slow and eventually stop the pandemic #COVID19

Novartis Cancer (@novartiscancer) 's Twitter Profile Photo

We’re relentlessly #ReimaginingMedicine for patients with blood cancers and disorders. Learn more about our bold approaches in hematology at #EHA25Virtual bit.ly/3i47O14

Novartis (@novartis) 's Twitter Profile Photo

Investing in our planet supports our purpose to reimagine medicine to improve and extend people’s lives. Thank you Enel Green Power for supporting us on our journey.

Novartis (@novartis) 's Twitter Profile Photo

No courage, no progress. To develop one of the world’s most powerful microscopes, Prisca Liberali from the Friedrich Miescher Institute put her scientific career at risk. Live.Magazine met with her to uncover what gave her the confidence to do so. Read the full story now!

Thomas Lang; MD, PhD (@thomaslangdr) 's Twitter Profile Photo

Had an incredible experience at #ACC23 this past week! Walking away from this event with a renewed sense of energy! Thanks to everyone who made this trip so memorable! #Novartis #HealthCare

Had an incredible experience at #ACC23 this past week! 

Walking away from this event with a renewed sense of energy! Thanks to everyone who made this trip so memorable!

#Novartis #HealthCare
Thomas Lang; MD, PhD (@thomaslangdr) 's Twitter Profile Photo

Sharing an incredible video that shares how Novartis and Payal Sharma - Laad are committed to creating #healthcare access in rural India! Watch the video and explore our #CollectiveCommitment to #EmbraceEquality at #Novartis: bit.ly/3T9Anx0 #WHM2023

Novartis News (@novartisnews) 's Twitter Profile Photo

Novartis announces topline data from a Phase III study of a CDK4/6 inhibitor in a broad population of people diagnosed with stage II and III HR+/HER2- early #BreastCancer #NovartisNews